Neurocrine Biosciences News

Neurocrine Biosciences, Inc. today announced their highly selective vesicular monoamine transporter 2 inhibitor, NBI-98854, will be advanced in clinical development.

CareFusion said it has learned of an effort to acquire up to 4 million of its shares through a a oemini-tendera offer but is recommending that shareholders turn down the deal.

Shares of Neurocrine Biosciences Inc. lifted in after-hours trading after the San Diego-based company said its endometriosis treatment proved safe and effective in its fifth Phase 2 clinical trial.

Neurocrine Biosciences, Inc. today announced top-line efficacy and safety results from the Tulip PETAL Study , its fifth Phase 2 clinical trial using its proprietary, orally-active nonpeptide Gonadotropin-Releasing Hormone receptor antagonist, elagolix, in patients with endometriosis.

BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has Healthcare stock news and updates to its calendar database of Clinical Trials and upcoming FDA approvals & decisions.

Neurocrine Biosciences, Inc. October 29, 2009 08:30 a.m. ET Executives Kevin Gorman - President and CEO Jane Sorensen - IR Tim Coughlin - VP and CFO Analysts Brian Abrahams - Oppenheimer & Company Craig Gordon - Cowen and Company Presentation Operator Good day everyone and welcome to today's program.

The report also includes M&A statistics and recent partnering news updates by date.

Neurocrine Biosciences, Inc. announced today that the Company will report its third quarter 2009 financial results after the Nasdaq market closes on Wednesday, October 28, 2009.

BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has Healthcare stock news and updates to its calendar database of Clinical Trials and upcoming FDA approvals & decisions.

Neurocrine Biosciences Inc. has secured a commitment from Kingsbridge Capital Ltd.

Neurocrine Biosciences, Inc. announced today that the Company has entered into a Committed Equity Financing Facility with Kingsbridge Capital Limited, a private investment group.

Neurocrine Biosciences announced an agreement under which private investment group Kingsbridge Capital will buy up to $75 million worth of newly issued Neurocrine stock over the next three years.

Neurocrine Biosciences, Inc. July 30, 2009 8:30 am ET Executives Kevin Gorman - President and CEO Jane Sorensen - IR Tim Coughlin - VP and CFO Analysts Brian Abrahams - Oppenheimer & Company Phil Nadeau - Cowen & Company Tommy Nuane [ph] - Piper Jaffray Larry Smith - DLS Research Presentation Operator Good morning and welcome to Neurocrine ...

Companies mentioned in this article: Neurocrine Biosciences, Inc. SAN DIEGO, July 27 /PRNewswire-FirstCall/ -- Neurocrine Biosciences announces the following Webcast: What: Neurocrine Biosciences Webcast When: July 30, 2009 @ 8:30am EDT Where: http://www.videonewswire.com/event.asp?id=60921 How: Live over the Internet -- Simply log on to the web at ...

BUYINS.NET / www.squeezetrigger.com is monitoring the performance of all stocks with earnings being released in the coming weeks and determining how the stocks have performed before their last 12 quarterly, 6 quarterly and July/August earnings reports.

BUYINS.NET / www.squeezetrigger.com is monitoring the performance of all stocks with earnings being released in the coming weeks and determining how the stocks have performed before their last 12 quarterly, 6 quarterly and July/August earnings reports.

NBIX's Elagolix Moving Forward By: Jason Napodano, CFA 2 ) Share Just recently, Neurocrine Bio presented results from the full twelve month analysis of the Petal-603 study, which includes data from the six months on treatment and six months follow-up period.

The first clinical abstract presentation reviews the results of a Phase I study in which elagolix was evaluated over six weeks in 60 healthy premenopausal women.